Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review
Chunmei Xiao,* Fangye Xu,* Rong Wang, Qi Liang, Kai Shen, Jiali Xu, Lianke Liu Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lianke...
Guardado en:
Autores principales: | Xiao C, Xu F, Wang R, Liang Q, Shen K, Xu J, Liu L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dc223551952b48859f6e1a19412157b0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Meng Yuan, et al.
Publicado: (2021) -
Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report
por: He Jian, et al.
Publicado: (2021) -
Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
por: Lixuan Cui, et al.
Publicado: (2021) -
Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles
por: Cui Y, et al.
Publicado: (2016) -
Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
por: Wang J, et al.
Publicado: (2021)